News, Short Squeeze, Breakout and More Instantly...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that health economics and outcomes research (HEOR) comparing the cost-effectiveness of the Company’s 3-anti...
- VBI’s 3-antigen adult HBV vaccine available in the U.S. as PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] and now approved in the European Union (EU)/European Economic Area (EEA) as PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)] - New data from VBI&...
PreHevbri™ is the only approved 3-antigen hepatitis B vaccine for adults in the EU and EEA Approval follows the positive opinion granted by European Committee for Medicinal Products for Human Use (CHMP) in February 2022 Regulatory review in the United Kingdom is ongoing...